Abstract: To provide an electrode for non-aqueous electrolyte batteries, which traps hydrogen sulfide gas, generated from the inside thereof for some reason, in the electrode, and suppresses the outflow of hydrogen sulfide gas to the outside of the battery. An electrode for lithium ion batteries includes a coating material which contains a silanol group and is present on at least a surface of an active material layer. The active material layer contains a sulfur-based material and a resin-based binder. The sulfur-based material is an active material capable of alloying with lithium metal or an active material capable of occluding lithium ions. The coating material containing the silanol group is a silicate having a siloxane bond or a silica fine particle aggregate having a siloxane bond as a component.

Abstract: The present invention provides an antibody that binds to an NTCP, capable of inhibiting infection of human hepatocytes with hepatitis B virus (HBV) particles. The present invention also provides an antibody that binds to an NTCP, capable of inhibiting infection of human hepatocytes with hepatitis B virus (HBV) particles, the antibody having a reduced effect on bile acid transport by NTCP.

Abstract: The object of the present invention is to provide a therapeutic agent for treating hormone therapy-resistant, treatment-resistant cancers, and a method of the treatment of hormone therapy-resistant, treatment-resistant cancers. The problem can be solved by a pharmaceutical composition including a compound represented by the formula (1) or a salt thereof or a compound represented by the formula (2) or (3) or a salt thereof, as an active ingredient for treating prostate cancer. Furthermore, the pharmaceutical composition of the present invention can effectively treat not only hormone therapy-resistant prostate cancer or breast cancer but also non-hormone therapy-resistant prostate cancer or breast cancer and Castration-resistant prostate cancer or treatment-resistant breast cancer caused by other mechanisms.

Abstract: This invention relates to an agent for inducing a callus comprising a compound represented by Formula (I) or a hydrolysis product of an amide bond thereof: wherein Ar1 represents phenyl substituted with substituent or substituents selected from alkoxy and methylenedioxy; Ar2 represents phenyl substituted with halogen; R1 and R2 each represent hydrogen, alkyl, cyano, or carboxyl; R1 and R2 may together form oxo; R3 to R10 each represent hydrogen or methyl; and R3 and R4, R5 and R6, R7 and R8, and/or R9 and R10 may together form oxo; a method for inducing a callus and a method for plant transformation using such agent for inducing a callus.

Abstract: To provide an electrode for non-aqueous electrolyte batteries, which traps hydrogen sulfide gas, generated from the inside thereof for some reason, in the electrode, and suppresses the outflow of hydrogen sulfide gas to the outside of the battery. An electrode for lithium ion batteries includes a coating material which contains a silanol group and is present on at least a surface of an active material layer. The active material layer contains a sulfur-based material and a resin-based binder. The sulfur-based material is an active material capable of alloying with lithium metal or an active material capable of occluding lithium ions. The coating material containing the silanol group is a silicate having a siloxane bond or a silica fine particle aggregate having a siloxane bond as a component.

Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.

Abstract: This invention relates to an agent for inducing a callus comprising a compound represented by Formula (I) or a hydrolysis product of an amide bond thereof: wherein Ar1 represents phenyl substituted with substituent or substituents selected from alkoxy and methylenedioxy; Ar2 represents phenyl substituted with halogen; R1 and R2 each represent hydrogen, alkyl, cyano, or carboxyl; R1 and R2 may together form oxo; R3 to R10 each represent hydrogen or methyl; and R3 and R4, R5 and R6, R7 and R8, and/or R9 and R10 may together form oxo; a method for inducing a callus and a method for plant transformation using such agent for inducing a callus.

Abstract: This invention relates to an agent for inducing a callus comprising a compound represented by Formula (I) or a hydrolysis product of an amide bond thereof: wherein Ar1 represents phenyl substituted with substituent or substituents selected from alkoxy and methylenedioxy; Ar2 represents phenyl substituted with halogen; R1 and R2 each represent hydrogen, alkyl, cyano, or carboxyl; R1 and R2 may together form oxo; R3 to R10 each represent hydrogen or methyl; and R3 and R4, R5 and R6, R7 and R8, and/or R9 and R10 may together form oxo; a method for inducing a callus and a method for plant transformation using such agent for inducing a callus.

Abstract: The present invention concerns: a plant growth-promoting agent comprising a compound represented by Formula (I) or a salt thereof: wherein Ar1 represents a substituted or unsubstituted phenyl group, NZ represents a nitrogen-containing heterocyclic ring group or an acyclic nitrogen-containing group having a partial structure of the nitrogen-containing heterocyclic ring group, n is 0, 1, or 2, R1 and R2 each represent a hydrogen atom, a substituted or unsubstituted C1-3-alkyl group, a cyano group, or a carboxyl group, R1 and R2 may together form an oxo group, and when n is 2, R1 or R2 may be the same or different; and a method for promoting plant growth using the plant growth-promoting agent.

Abstract: According to the present invention, a transgenic plant, wherein expression of the BSS1 gene having activity to bind to a BIL1 protein to inhibit the transfer of the BIL1 protein into the nucleus so as to down-regulate brassinosteroid signaling is suppressed or promoted, and a method for regulating plant growth, wherein expression of the BSS1 gene in a plant body is suppressed or promoted, are provided.

Abstract: The present invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.

Abstract: The present invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.

Abstract: The invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.

Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.

Abstract: The invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.

Abstract: An object of the present invention is to elucidate the mechanism of plant growth regulation by brassinosteroid and the mechanism of transfer of the BIL1 protein that is the master transcription factor of brassinosteroid signaling into the nucleus, discover new factors involved in the mechanisms, and using the factors for plant growth regulation, thereby increasing production of plant biomass or crop. According to the present invention, a transgenic plant, wherein expression of the BSS1 gene having activity to bind to a BIL1 protein to inhibit the transfer of the BIL1 protein into the nucleus so as to down-regulate brassinosteroid signaling is suppressed or promoted, and a method for regulating plant growth, wherein expression of the BSS1 gene in a plant body is suppressed or promoted, are provided.

Abstract: The present invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.

Abstract: Using a nucleic acid construct, association of a polypeptide with a sequence coding therefor and screening of a polypeptide that binds to a target substance are carried out, which nucleic acid construct comprises a 5?-untranslated region and a coding region, wherein the above-mentioned coding region comprises a sequence coding for a polypeptide subjected to be displayed, a sequence coding for a first nucleic acid binding polypeptide, and a sequence coding for a second nucleic acid binding polypeptide; the above-mentioned 5?-untranslated region comprises a first sequence capable of binding to a first nucleic acid binding polypeptide and a second sequence capable of binding to second nucleic acid binding polypeptide; and, when the above-mentioned nucleic acid construct is introduced in a translation system, a fusion protein translated from the coding region of the above-mentioned nucleic acid construct forms a complex with an RNA corresponding to the above-mentioned nucleic acid construct.

Abstract: Disclosed is a novel compound represented by formula (1) below.

Abstract: The present invention concerns: a plant growth-promoting agent comprising a compound represented by Formula (I) or a salt thereof: wherein Ar1 represents a substituted or unsubstituted phenyl group, NZ represents a nitrogen-containing heterocyclic ring group or an acyclic nitrogen-containing group having a partial structure of the nitrogen-containing heterocyclic ring group, n is 0, 1, or 2, R1 and R2 each represent a hydrogen atom, a substituted or unsubstituted C1-3-alkyl group, a cyano group, or a carboxyl group, R1 and R2 may together form an oxo group, and when n is 2, R1 or R2 may be the same or different; and a method for promoting plant growth using the plant growth-promoting agent.